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Abstract
This work investigated the replication kinetics of the four dengue virus serotypes (DEN-1 to DEN-4), including dengue virus
type 4 (DEN-4) recovered from an infectious cDNA clone, in Vero cells and in MRC-5 cells grown on Cytodex 1 microcarriers.
DEN-1 strain Hawaii, DEN-2 strain NGC, DEN-3 strain H-87, and DEN-4 strain H-241 , and DEN-4 strain 814669 derived from
cloned DNA, were used to infect Vero cells and MRC-5 cells grown in serum-free or serum-containing microcarrier cultures.
Serum-free and serum-containing cultures were found to yield comparable titers of these viruses. The cloned DNA-derived
DEN-4 started genetically more homogeneous was used to investigate the genetic stability of the virus propagated in Vero
cells and MRC-5 cells. Sequence analysis revealed that the DEN-4 propagated in MRC-5 cells maintained a high genetic
stability, compared to the virus propagated in Vero cells. Amino acid substitutions of Gly104Cys and Phe108Ile were detected
at 70%, 60%, respectively, in the envelope (E) protein of DEN-4 propagated in Vero cells, whereas a single mutation of
Glu345Lys was detected at 50% in E of the virus propagated in MRC-5 cells. Sequencing of multiple clones of three separate
DNA fragments spanning 40% of the genome also indicated that DEN-4 propagated in Vero cells contained a higher
number of mutations than the virus growing in MRC-5 cells. Although Vero cells yielded a peak virus titer approximately 1 to
17 folds higher than MRC-5 cells, cloned DEN-4 from MRC-5 cells maintained a greater stability than the virus from Vero
cells. Serum-free microcarrier cultures of MRC-5 cells offer a potentially valuable system for the large-scale production of
live-attenuated DEN vaccines.
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Introduction
The four dengue serotype viruses (DEN-1 to DEN-4) (genus
flavivirus, family Flaviviridae) are single stranded, positive-sense RNA
viruses that are transmitted to humans primarily by Aedes aegypti
mosquitoes. The RNA genome contain sequences coding for three
structural protein genes (core C, precursor membrane prM, and
envelope E), seven non-structural protein genes (NS1, NS2A,
NS2B, NS3, NS4A, NS4B, NS5), and the flanking non-translating
regions. DEN infection in humans causes a spectrum of illnesses,
ranging from dengue fever (DF) to dengue hemorrhagic fever
(DHF) and dengue shock syndrome (DSS) [1]. Approximately 50–
100 million infections, including 250,000 cases of DHF with
fatality rates varying from ,1% to 5%, occur every year mostly in
tropical and subtropical areas [2]. Dengue is endemic in South-
east Asia, where the severe form of DHF/DSS frequently
associated with secondary DEN infections is the major cause of
hospitalization of young children [3]. A safe and effective dengue
vaccine is still not available for prevention of DEN infection.
The current DEN immunization strategy favors the use of live-
attenuated vaccines which offer the advantage of a single dose,
delivering a complete set of protective antigens and achieving a
long-lasting immunity [4]. Further, the use of a tetravalent DEN
vaccine against each of the four serotypes would have the
possibility to minimize the risk of severe dengue [4]. Wild type
DEN-1, DEN-2, DEN-3, DEN-4 strains have been attenuated by
serial passage in primary dog kidney cells (or monkey kidney cells)
[5–7] and final vaccines were produced in fetal rhesus lung cells or
Vero cells [8–10]. Extensive clinical trials have demonstrated that
each monovalent DEN vaccine appeared to be immunogenic and
safe [6–10]. However, data obtained from clinical trials with a
tetravalent vaccine formulation have not shown the predicted
response, as immune imbalance or reactogenicity occurred for
certain DEN serotypes [6,7]. Several other vaccine researchers
also have applied the cDNA cloning added by chimeric virus
technology and strategic modifications to generate viruses with the
growth restriction phenotype in the genetic background of
attenuated virus (for example, using DEN-4 with a deletion in 39
NTR, attenuated 17D yellow fever vaccine or DEN-2 strain PDK-
53) [11–20]. All of these cDNA-derived candidate DEN vaccines
have been produced in Vero cells, recently certified for vaccine
production. Although clinical trails with a few of these monotypic
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reactogenicity, data from studies with such vaccines of other
serotypes or a tetravalent vaccine formulation are still not
available. Potential replication interference among the four
serotype vaccine components that results in immune imbalance
remains a concern.
Replication interference could result from loss or increase of
infectivity due to genetic instability and accumulation of mutations
in certain vaccine components. Passages of DEN viruses or their
derived chimeras in Vero cells [21,22] have been shown to
generate mutations specific for host cell adaptation, virus
attenuation, or other properties yet to be characterized. Recently,
spot-check sequencing in the manufacturing of chimeric DEN-2
PDK-53 vaccine components has detected loss of attenuating
mutation markers in a number of seed stocks during first several
passages in Vero cells and these vaccine seeds were not
appropriate for use [23]. It is also possible that passage of virus
in certain cells produces host-cell specific mutations which could
contribute to host cells’ innate immunity response in the vaccinees.
The use of appropriate cell substrates and methods for culturing
these cells for production of vaccines represents a critical factor
affecting the maximum viral yield, genetic stability, immunoge-
nicity, and ultimately vaccine safety and economic feasibility.
Recently, a serum-free medium has been developed to support
the growth of Vero cells on solid microcarriers and produce a high
final yield for reovirus [24], Japanese encephalitis virus [25], and
enterovirus type 71 [26,27]. Although an attempt has not been
made for producing DEN vaccines, human diploid MRC-5 cells
have been already used for the production of several live-virus
vaccines such as oral polio, rubella, small pox, and varicella zoster
[28]. This study investigated Vero cells and MRC-5 cells for the
production of the four wild type DEN serotypes, including DEN-4
derived from an infectious DNA clone. We focused on the
processes of cell culture using microcarrier systems which can be
adapted for large-scale production and serum-free medium to
avoid potential contamination from bovine serum. Currently,
several panels of tetravalent DEN vaccine candidates have been
derived from viruses of diverse genetic background responsible for
growth restriction [13,16]. In order to simplify interpretation of
results, cloned DNA derived wild type DEN-4 was used for
comparison of progeny genetic stabilities from passages of the virus
in Vero cells and in MRC-5 cells. This strategy using cloned DNA-
derived wild type rather than attenuated DEN-4 has been
previously used to investigate the genetic mutations of chimeric
DEN-4 after Vero cell adaptation [21]. Our present studies show
that Vero cells yielded a peak virus titer approximately 1 to 17
folds higher than MRC-5 cells, and DEN-4 propagated in MRC-5
cells maintained a greater stability than the virus propagated in
Vero cells. Serum-free microcarrier cultures of MRC-5 cells offer a
potentially valuable system for the large-scale production of live-
attenuated DEN vaccine.
Results
Microcarrier cultures of Vero cells and MRC-5 cells grown
in serum-free and serum-containing media
Solid microcarriers (Cytodex 1) have been shown to support the
growth of Vero cells in either serum-containing or serum-free
medium [24–27]. To investigate whether microcarriers also
support the growth of MRC-5 cells, MRC-5 cells were seeded at
an initial density of 3610
5 cell/ml in serum-containing medium or
6610
5 cells/ml in serum-free medium on microcarriers. Vero cells
were also seeded at same density in the respective medium as a
control. Three days after incubation, both the Vero cells and
MRC-5 cells adhered to the entire surface of the microcarrier
beads, reaching confluency as seen microscopically (Fig. 1). The
cell density was determined at 1.6610
6 cells/ml in serum-free
medium or 1.4610
6 cells/ml in serum-containing medium for
MRC-5 cells, compared to 1.7610
6 cells/ml in serum-containing
medium or 1.8610
6 cells/ml in serum-free medium for Vero cells.
Doubling the cell density in serum-free culture was needed to
support the cell growth on microcarriers. Increased cell seed lot
consumption in serum-free cultures is a continuing problem in
vaccine manufacturing processes, particularly in large-scale
microcarrier cultures. We are currently optimizing additional
components in the M-VSFM medium to reduce the cell density for
initial inoculation in serum-free microcarrier cultures (data not
shown).
Production of DEN-1, DEN-2, DEN-3 and DEN-4 in
infected Vero cells and MRC-5 cells
Production of DEN-1 strain Hawaii, DEN-2 strain NGC, DEN-
3 strain H-87 and DEN-4 strain H-241 in Vero cells and in MRC-
5 cells grown in serum-containing and serum-free media was
studied. Figs. S2, S3, S4 and S5 show the cell growth and virus
replication curves at a multiplicity of infection (MOI) of 0.01 in
serum-free and serum-containing media. In each case the cell
density decreased gradually during the 10-day period following
virus infection, and no appreciable differences were observed
between cells growing in serum-free medium and in serum-
containing cultures. The virus yields from Vero cells was 1 to 17
folds higher than that from MRC-5 cells for each serotype virus
(Table 1), whether in serum-containing or serum-free medium.
Compared to DEN-2 NGC, DEN-3 H87 and DEN-4 H241
produced a 10
3-t o1 0
4-fold lower viral yield from Vero cells or a
10
2-t o1 0
3-fold lower yield from MRC-5 cells in serum-containing
medium. The serotype difference was probably not responsible for
the low viral yields, as the DEN-4 strain derived from cDNA
replicated as efficiently as DEN-2. A plausible reason for the
unexpected low yields is that these viruses have acquired mutations
during passages in cultured cells or in animals. This probability
was supported from the analysis of viral yields in similar infections
with the wild type DEN-4 derived from a cDNA clone (see next
section). Importantly, higher viral yields from Vero cells or MRC-
Figure 1. Vero and MRC-5 cell growth on Cytodex 1 micro-
carriers in serum-free cultures. Microscopic observation shows (A)
Vero and (B) MRC-5 cells on microcarriers in M-VSFM after 3 days
culture.
doi:10.1371/journal.pone.0001810.g001
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four DEN serotypes in serum-free medium than in serum-
containing media.
Propagation of cloned DNA-derived DEN-4 in Vero cells
and MRC-5 cells and sequence analysis of progeny DEN-4
DEN-4 strain 814669 recovered from cloned DNA was
propagated in microcarrier cultures of both cell lines. Infection
with the virus was carried out at the same multiplicity as described
earlier. The density of Vero cells or MRC-5 cells decreased
steadily during the subsequent 10-day period, indicating that both
cells were readily infected (Fig. S5). The viral yields of cloned DNA
derived DEN-4 in microcarrier cultures of both cells were
comparable to that observed for DEN-2 NGC. There were
appreciable differences in the viral yields between cell cultures in
serum-containing or serum-free medium (Table 1). Vero cells
produced a virus titer of cloned DEN-4 increased by 11 folds
(serum-free medium) and 14 folds (serum-containing medium) as
compared to MRC-5 cells.
DEN-4 derived from cloned DNA was propagated in the
microcarrier cultures of Vero cells or MRC-5 cells in serum-free or
serum-containing medium for 4 days. The nucleotide sequence of
progeny DEN-4 was determined from a single cDNA clone
representing each of the four overlapping regions, designated as
W01/W02R, W03/W04R, W05/W06R, W07/W08R, spanning
the entire DEN genome. Each progeny DEN-4 sequence was
compared with the parent DEN-4 DNA sequence (GenBank
accession number: AF375822). The results in Table 2 revealed
that there were 18 nucleotide mutations resulting in 13 amino acid
changes in DEN-4 propagated in Vero cells using serum-
containing medium, and 11 nucleotide mutations resulting in 6
amino acid changes in DEN-4 propagated in Vero cells grown in
serum-free medium. In contrast, there was only one nucleotide
mutation resulting in one amino acid change in each DEN-4
propagated in MRC-5 cells grown in serum-containing medium or
in serum-free medium. None of the amino acid changes was
identical between the DEN-4 propagated in Vero cells grown in
serum–containing medium or in serum-free medium. Further,
these amino acid changes in DEN-4 occurred in nearly all gene
segments and the number of mutations, ie., a total of 6 each in
NS3 and in NS4B-NS5, appeared to reflect the large size of the
gene segments. This suggests that a host range selection of
mutations was probably not involved. By comparison, there was
only one amino acid change in the entire genome of DEN-4 from
MRC-5 cells whether or not serum was present in the medium.
This finding indicates that a greater genomic stability of cloned
DNA-derived DEN-4 was observed when the virus was propa-
gated in MRC-5 cells, compared to virus propagated in Vero cells.
Sequences of multiple clones of three genomic
fragments
Since the previous DEN-4 sequence determination was made
from one DNA clone representing each of the four genome
segments, to further investigate the genome stability of DEN-4
during passages in Vero cells and in MRC-5 cells, sequences of
multiple clones were determined. The DNA-derived DEN-4
viruses were obtained in Vero cells or in MRC-5 cells at three
consecutively passages after in vitro RNA transfection (as P1, P2, P3
samples). P1 and P2 viruses were harvested from cells grown in T
flask cultures and the P3 passage virus was from a microcarrier
culture. Multiple clone sequencings were conducted on the three
genomic fragments (WE1/W02R, W28/W29R, W21/W23R)
because most mutations identified earlier were localized in these
fragments. These fragments are: (i) WE1/W02R, consisting of the
full-length E gene and the NS1 gene portion encoding the first 152
amino acids; (ii) W28/W29R, consisting of part of NS3 gene
encoding the amino acids 42–455; and (iii) W21/W23R, consisting
of the entire NS4B gene and the NS5 gene portion encoding the
first 180 amino acids. A total of 180 independent clones were
obtained for sequence determination in this study.
No nucleotide mutation was found in the WE1/W02R (E-NS1)
fragments of P1 and P2 passages from Vero or MRC-5 cells
(Table 3). However, there were 7 nucleotide differences that
resulted in 5 amino acid mutations in E protein at G104C, F108I,
G427R, V439F, and V463L from Vero cells after three passages.
Likewise, there were 3 nucleotide differences including 3 amino
acid mutations in E protein at E345K, N362K, and G427R from
MRC-5 cells (Table 3). The mutation frequencies of G104C and
F108I in Vero cells and E345K in MRC-5 cells were 70%, 60%,
and 50% respectively. In the W28/W29R (NS3) fragments, the P3
viruses from microcarrier cultures revealed 16 mutations resulting
in 11 amino acid changes in Vero cells and 3 mutations resulting
in 2 amino acid changes in MRC-5 cells. Each of these mutations
in the NS3 protein occurred at a frequency of 10% except E341G
Table 1. The maximum virus titers for four-serotype DEN virus strains and the cloned DNA-derived DEN-4 viruses in Vero cells and
MRC-5 cells on microcarriers, in serum-containing and serum-free media.
Virus titer (pfu/ml) in Vero cells
DEN-1 DEN-2 DEN-3 DEN-4 DEN-4
(HAWAII) (NGC) (H-87) (H-241) (DNA clone)
DMEM+10%FBS (1.760.1)610
6 (1.260.0)610
7 (1.360.1)610
4 (2.060.2)610
3 (1.660.3)610
7
M-VSFM (4.060.1)610
6 (2.260.0)610
7 (3.060.1)610
4 (2.960.2)610
3 (1.460.1)610
7
Virus titer (pfu/ml) in MRC-5 cells
DEN-1 DEN-2 DEN-3 DEN-4 DEN-4
(HAWAII) (NGC) (H-87) (H-241) (DNA clone)
DMEM+10%FBS (6.060.1)610
5 (6.860.3)610
5 (4.560.7)610
3 (2.560.7)610
2 (1.160.8)610
6
M-VSFM (7.760.1)610
5 (2.060.1)610
6 (1.360.3)610
4 (9.062.8)610
2 (1.260.1)610
6
doi:10.1371/journal.pone.0001810.t001
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fragment, there were 11 mutations resulting in 10 amino acid
changes in the P3 virus from Vero cells on microcarriers. The
mutations were found at L112F and A240V in the NS4B protein at
a frequency of 30%, while other mutations occurred at a
frequency of 10%. Interestingly, there was only 1 nucleotide
mutation resulting in 1 amino acid change in DEN-4 from MRC-5
cells grown on microcarriers at P3 (Table 5).
These results were then analyzed on the basis of amino acid
mutations detected in each of the three fragments sequenced. The
mean diversity and mean p-distance of amino acid mutations in
each genomic fragment of 10 independent clones were calculated
(Table 6). The numbers of amino acid mutations within the WE1/
W02R, W28/W29R, W21/W23R fragments respectively were 17,
12, 13 from Vero cells, and 7, 2, 0 from MRC-5 cells. The values
of mean diversity calculated for these three genomic fragments
were 0.31 (WE1/W02R), 0.29 (W28/W29R), and 0.31 (W21/
W23R) in Vero cells, as compared to 0.13 (WE1/W02R), 0.05
(W28/W29R), and 0 (W21/W23R) in MRC-5 cells. The values of
mean diversity calculated from MRC-5 cells were at least 2 folds
lowered than from Vero cells. Calculation of the p-distance based
on pair wise comparisons of amino acid sequences between clones
also showed the values of mean p-distance were 0.36 (range 0–
0.70) in Vero cells compared to 0.19 (range 0–0.50) in MRC-5
cells in the WE1-W02R fragment; 0.56 (range 0–0.12) in Vero
cells compared to 0.13 (range 0–0.50) in MRC-5 cells in the W28-
W29R fragment; 0.50 (range 0–1.40) in Vero cells compared to 0
(range 0) in MRC-5 cells in the W21-W23R fragment. All of these
data demonstrated that the cloned DEN4 propagated in MRC-5
cells were more stable than those propagated in Vero cells.
Discussion
This work has investigated the replication kinetics of four-
serotype and cloned DNA-derived DEN viruses in Vero and
MRC-5 cells. Vero (African green monkey kidney) cells are
polyploidy (recently certified as cell hosts for producing DEN
vaccines) and MRC-5 (human fetal lung fibroblast cells) are
diploid. Both cell lines have been already used to develop several
human vaccines [28], and Vero cells are currently used for
candidate DEN vaccine production. However, viral yield and
genetic stability of DEN viruses have not been systematically
compared between Vero and MRC-5 cell lines.
High titers of DEN-1 (HAWAII) and DEN-2 (NGC) but
relatively low titers of DEN-3 (H-87) and DEN-4 (H-241) were
obtained in this study in either Vero cells or MRC-5 cells,
although both cells were grown to a similar density on
microcarrieres prior to virus infection. A possible explanation is
that the DEN-4 (H-241) virus strain used was the non mouse-
adapted strain rather than the prototype mouse-adapted strain
since the non mouse-adapted strain was associated with two E
protein mutations (Ile for Thr-155, Leu for Phe-401) [29]. This
study obtained high titers (1,2610
6 pfu/ml) of cloned DEN-4
(81466 strain) in both Vero cells and MRC-5 cells. The viral yield
of cloned DEN-4 (81466 strain) produced in MRC-5 cells on
microcarriers (at P3) was approximately 10 folds lower and had
only one amino acid change compared to those in Vero cells with
thirteen and six amino acid mutations in serum-free and serum-
containing cultures, respectively (Table 2). Almost no P1 and P2
virus mutations in the Vero and MRC-5 cells grown in T flasks
were found by sequencing of multiple clones (Tables 3,5). The
increased genetic mutations of cloned DEN4 observed in Vero
cells were probably caused by passage number or high-density
microcarrier culture rather than the increased virus yield.
Comparative mutation rate in this study was based only on the
genomic sequences of the cloned DNA-derived DEN4 from
passages 1 through 3, the latter representing microcarrier culture
viruses. This study did not investigate the genomic characteristics
of the non-cloned wild type viruses such as the DEN-1 (HAWAII),
DEN-2 (NGC), DEN-3 (H-87), and DEN-4 (H-241) strains used
for the virus yield studies in Figs S1, S2, S3 and S4. Thus, only the
cloned DNA-derived DEN-4 virus started genetically more
homogeneous was analyzed. The genomic changes in the cloned
DEN-4 viruses in Table 2 indicate that the mutations occurred in
C, E, NS1, NS2A, NS3, NS4A, NS4B, and NS5 but not in the 59-
NTR or 39-NTR regions. This result is partly agreed with other
related reports of mutations in C, M, E, NS2A, NS4B and NS5
regions for the DEN-2/DEN-4 chimeric virus [30], and in 59
NTR, C, E, NS1, NS3, NS4A, NS4B and NS5 regions for the
chimeric DEN-4/Japanese encephalitis virus [31]. Multiple
cloning experiments showed that most mutations were at 10%
frequency and occurred in the third passage (P3) using
Table 2. Genomic sequences of the cloned DNA-derived
DEN-4 viruses in Vero and MRC-5 cells on microcarriers, in
serum-containing and serum-free media.
Vero cells
DMEM+10%FBS M-VSFM
Gene Mutation Gene Mutation
Nucleotide
Amino
acid Nucleotide
Amino
acid
C C228T Silent
E A628G K210E E T1443C Silent
NS1 T923C V308A NS1 C366A P122T
NS1 T946C C316R NS1 C777T Silent
NS2A T230C M77T
NS2B A156G Silent
NS3 A27G Silent NS3 T240C Silent
NS3 T793C F265L NS3 A625G R209G
NS3 A1202G D401G NS3 A1320G Silent
NS3 G1215A Silent NS3 A1348G T450A
NS3 G1283A C428Y
NS3 A2202G Silent
NS4A A330G I110M NS4A T211G F71V
NS4A T244C S82P
NS4B A336C L112F
NS5 A458T N153I NS5 A1708C K569Q
NS5 G476A G159E
NS5 A816C Silent
NS5 A1186G R396G
NS5 G1517A G506E
MRC-5 cells
DMEM+10%FBS M-VSFM
Gene Mutation Gene Mutation
Nucleotide Amino
acid
Nucleotide Amino
acid
NS5 C406T P136S E G1033A E345K
doi:10.1371/journal.pone.0001810.t002
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viruses propagated in Vero and MRC-5 cells at three consecutive passages using serum-free medium.
Passage Cell Virus gene segment Mutation
Frequency* Nucleotide position Amino acid position
P1 Vero - 0/10 No change No change
P2 Vero - 0/10 No change No change
P3 Vero E 7/10 G 310 T G 104 C
P3 Vero E 6/10 T 322 A F 108 I
P3 Vero E 2/10 G 1278 C G 427 R
P3 Vero E 1/10 G 1314 T V 439 F
P3 Vero E 1/10 G 1386 T V 463 L
P3 Vero E 1/10 G 1409 A Silent
P3 Vero E 4/10 T 1442 C Silent
P1 MRC-5 - 0/10 No change No change
P2 MRC-5 - 0/10 No change No change
P3 MRC-5 E 5/10 G 1033 A E 345 K
P3 MRC-5 E 1/10 C 1085 A N 362 K
P3 MRC-5 E 1/10 G 1278 A G 427 R
*10 clones were sequenced in each case.
doi:10.1371/journal.pone.0001810.t003
Table 4. Nucleotide and amino acid mutations in the W28-W29R (NS3) genetic fragment of the cloned DNA-derived DEN-4 viruses
propagated in Vero and MRC-5 cells at three consecutive passages using serum-free medium.
Passage Cell Virus gene segment Mutation
Frequency* Nucleotide position Amino acid position
P1 Vero - 0/10 No change No change
P2 Vero - 0/10 No change No change
P3 Vero NS3 1/10 T 150 C Silent
P3 Vero NS3 1/10 G 161 A R 54 K
P3 Vero NS3 1/10 C 304 G P 102 A
P3 Vero NS3 1/10 G 376 T V 126 L
P3 Vero NS3 1/10 A 391 G K 131 E
P3 Vero NS3 1/10 A 625 G R 209 G
P3 Vero NS3 1/10 A 663 G Silent
P3 Vero NS3 1/10 A 799 G T 267 A
P3 Vero NS3 1/10 A 998 G E 333 G
P3 Vero NS3 1/10 A 1007 G E 336 G
P3 Vero NS3 1/10 T 1017 C Silent
P3 Vero NS3 1/10 G 1020 C Silent
P3 Vero NS3 2/10 A 1022 G E 341 G
P3 Vero NS3 1/10 T 1078 G W 360 G
P3 Vero NS3 1/10 A 1320 G Silent
P3 Vero NS3 1/10 A 1348 G T 400 A
P1 MRC-5 - 0/10 No change No change
P2 MRC-5 - 0/10 No change No change
P3 MRC-5 NS3 1/10 C 633 G Silent
P3 MRC-5 NS3 1/10 C 668 T P 223 L
P3 MRC-5 NS3 1/10 G 909 T R 303 S
*10 clones were sequenced in each case.
doi:10.1371/journal.pone.0001810.t004
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Vero cells and the E-E345K in MRC-5 cells had mutation rates
exceeding 50% and the NS4B-L112F and NS4B-A240V in Vero
cells had mutation rates of 30%. These results conflict with the
high rate of NS3 gene mutation reported in a recent study of the
full-genomic sequences of several DEN-3 clinical isolates [32].
Reportedly, NS4B is a key determinant of Vero cell adaptation for
the intertypic-DEN chimeric viruses [21,31]. Our experiments
showed that the NS4B-L112F and NS4B-A240V mutations occur in
Vero cells at a frequency of only 30% (Table 5), which partially
correlates with other studies of infectious clone DEN viruses [22]
and 59-FU mutagenized DEN viruses [21]. However, the present
report found that the E-G104C, E-F108I mutations in Vero cells
and the E-E345K mutation in MRC-5 cells occurred at a higher
frequency than the NS4B-L112F and NS4B-A240V mutations in
Vero cells.
The DEN2-PDK-53-based chimeric viruses have recently been
characterized by multiple plaque selection and spot/genomic
sequencing [23]. The current data based on the first three passages
have already demonstrated a better genetic stability in MRC-5
cells than in Vero cells. Prompted by reports of success in
manufacturing the DEN2-PDK-53-based tetravalent vaccine in
certified Vero cells [23], the authors are currently investigating the
genetic stability of attenuated chimeric cloned viruses of four
serotypes to high passage levels. Passage numbers are limited
to less than 10 since live-attenuated vaccines require limited
passage levels from the seed virus to prevent unsafe virus reversion.
After all, the data obtained in this study at the third passage of
serum-free microcarrier cultures have already shown that the
DEN virus propagated in MRC-5 cells is genetically more stable
than in Vero cells. Therefore, despite the acceptance of Vero cells
for many candidate DEN vaccine productions, the current
Table 5. Nucleotide and amino acid mutations in the W21-W23R (NS4B-NS5) genetic fragment of the cloned DNA-derived DEN-4
viruses propagated in Vero and MRC-5 cells at three consecutive passages using serum-free medium.
Passage Cell Virus gene segment Mutation
Frequency* Nucleotide position Amino acid position
P1 Vero - 0/10 No change No change
P2 Vero - 0/10 No change No change
P3 Vero NS4B 1/10 C 192 T Silent
P3 Vero NS4B 1/10 G 253 A D 85 N
P3 Vero NS4B 3/10 A 336 C L 112 F
P3 Vero NS4B 3/10 C 719 T A 240 V
P3 Vero NS5 1/10 C 167 T S 56 F
P3 Vero NS5 1/10 C 238 T L 80 F
P3 Vero NS5 1/10 G 251 A R 84 K
P3 Vero NS5 1/10 A 270 C M 90 L
P3 Vero NS5 1/10 A 287 C N 96 T
P3 Vero NS5 1/10 A 296 G E 99 G
P3 Vero NS5 1/10 A 308 T Y 103 F
P1 MRC-5 NS4B 1/10 C 202 T P 101 L
P3 MRC-5 - 0/10 No change No change
*10 clones were sequenced in each case.
doi:10.1371/journal.pone.0001810.t005
Table 6. The number of amino acid mutations and the mean diversity for the three genetic fragments of the cloned DNA-derived
DEN-4 viruses propagated in Vero and MRC-5 cells in serum-free cultures.
Cell line WE1-W02R (E-NS1) W28-W29R (NS3) W21-W23R (NS4B-NS5)
total no. of amino acids=551 total no. of amino acids=420 total no. of amino acids=426
No. of
mutations
Mean
diversity
(%)
a p-distance (%)
b No. of
mutations
Mean
diversity
(%)
a p-distance (%)
b No. of
mutations
Mean
diversity
(%)
a p-distance (%)
b
Mean Range Mean Range Mean Range
Vero 17 0.31 0.36 0–0.70 12 0.29 0.56 0–1.20 14 0.31 0.50 0–1.40
MRC-5 7 0.13 0.19 0–0.50 2 0.05 0.13 0–0.50 0 0.00 0.00 0–0.00
aThe mean diversity is the number of substitutions divided by the total number of amino acids sequenced.
bp-distances were calculated by pair wise comparison of amino acid sequences between clones by the program MEGA.
doi:10.1371/journal.pone.0001810.t006
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offer a more stable system for DEN virus production. This study is
apparently the first to demonstrate that MRC-5 cells are a
potentially better cell host for live-attenuated DEN vaccine
production. These findings may be helpful in developing a
biomanufacturing process for DEN vaccine production using
high-density microcarrier cultures.
Materials and Methods
Cells and Media
Vero cells, MRC-5 cells and BHK-21 cells were obtained from
the Bioresource Collection and Research Center (BCRC), Food
Industrial Research and Development Institute, Hsinchu, Taiwan.
Vero cells and MRC-5 cells were grown in Dulbecco’s Modified
Essential Medium (DMEM) (Invitrogen) and BHK-21 cells were
grown in Eagle’s Minimum Essential Medium (EMEM) (Sigma)
supplemented with 10% heat-inactivated fetal bovine serum (FBS)
and 100 U/ml of penicillin G sodium-Streptomycin (Invitrogen).
Vero cells and MRC-5 cells were also cultured in serum-free
medium using M-VSFM serum free medium (Biogro) [24–27] plus
100 U/ml of penicillin G sodium-Streptomycin. No prior
adaptation in reduced serum concentrations was required for
serum free cultures. Trypsin inhibitor (GIBCO) was used at 0.25%
for cell detachment to protect cell damage by trypsin treatment
under serum-free conditions.
Viruses
DEN-1 virus (Hawaii), DEN-2 virus (NGC), DEN-3 virus (H-
87) and DEN-4 virus (H-241) were provided by the Center of
Disease Control, Department of Health, Taiwan. Stock viruses
were prepared from supernatants of infected C6/36 cells grown in
Hank’s MEM medium (GIBCO) plus supplements 6 days post-
infection at 28uC [33]. The plasmid of DEN-4 strain 814669
contained the full-length genomic sequence [12]. The plasmid was
first linearized by cleavage with restriction enzyme Kpn I and then
added to a transcription reaction mixture (Promega kit) containing
m
7G(59)ppp(59)G (Merck) for cap addition at the RNA 59-end.
After incubation at 37uC for 1.5 hour, the RNA product was
purified with TRIzol reagent (Invitrogen) according to manufac-
turer’s instructions. Prior to RNA transfection, subconfluent Vero
cells and MRC-5 cells in a 24-well plate were rinsed once with
serum-free medium and then covered with 0.3 ml of DMEM
medium per well. The transfection mixture was prepared by
adding 4 ml of DMRIE-C reagent (Invitrogen) to 1 ml of DMEM,
then mixing with 10 mg of the RNA product. The transfection
mixture was added directly to cell monolayers. After 18 hours
incubation at 37uC, either DMEM+10% FBS or M-VSFM
medium were added to the well. Eight days after transfection,
culture supernatants were collected. All virus stocks were stored at
280uC freezer for further analysis.
Microcarrier cultures
Cytodex 1 microcarriers (Amersham Biosciences) were pre-
pared according to manufacturer’s instructions. Briefly, the
Cytodex 1 microcarriers were immersed in phosphate buffer
saline (PBS) for at least three hours and autoclaved for 15 min
before each experiment. The autoclaved microcarriers were
washed twice with the culture medium. Bellco spinner flasks
(100-ml) were used in the experiments for a working volume of
50 ml. The spinner flasks were stirred at 60 rpm and placed inside
an incubator with 5% CO2 at 37uC. Cells were detached from
tissue culture flasks using trypsin-EDTA, and then transferred to a
spinner flask containing 2g/l Cytodex 1 microcarriers. Starting cell
densities were 3610
5 cells/ml in serum-containing cultures and
6610
5 cells/ml in serum-free cultures. The cell cultures were
infected after 3 day inoculation and by replacing 70% of the
medium with fresh medium containing the virus inoculum at a
multiplicity of infection (MOI) of 0.01. Inoculation continued
without further replacement with fresh medium or addition of
supplements.
Determination of cell density and virus titer
The number of cells attached to the microcarriers was
determined by nuclei staining. Briefly, a 1-ml sample of the
microcarrier culture was taken and centrifuged at 200 g for 5 min
to remove the supernatant. The pellets were treated with 1 ml
0.1 M citric acid [containing 0.1% (w/v) crystal violet] and
incubated at 37uC for 1 hour. The released nuclei were counted in
a hemocytometer. The virus titer was measured by 10-fold serial
dilutions of the culture supernatant in duplicate infections of
BHK-21 cell monolayers in a 6-well plate. After 1 hour incubation
at 37uC, 4 ml of medium containing 10% FBS and 1.1%
methylcellulose (4 ml/well) was added to each well. Virus plaques
were stained with naphthol blue black dye six days after
incubation. The infectivity titer in plaque forming units (pfu) per
ml was determined.
Sequencing the entire genome of cloned DNA-derived
DEN-4
Viral RNA was extracted from culture supernatants using
TRIzol reagent (Invitrogen), and the cDNA synthesized by reverse
transcription using Superscript II RTase (Invitrogen). The double-
stranded DNA was then generated by polymerase chain reaction
(PCR) using PlatinumH Pfx DNA polymerase (Invitrogen). Four
overlapping fragments that span the entire DEN genome were
produced using 4 sets of forward and reverse primers: (i) W01/
W02R, (ii) W03/W04R, (iii) W05/W06R, and (iii) W07/W08R as
listed in Table S1. The DNA products were purified by Gel/PCR
DNA fragments extraction kit (Geneaid, Taiwan), cloned into the
pGEM T-easy vector (Promega). The nucleotide sequences of each
of the four fragments cloned into the pGEM T-easy vector (from
two upstream promoters SP6 and T7 at both ends of the vector)
were determined by Mission Biotech Inc., Taipei, Taiwan. The
cloned DNA segments that span the entire DEN genome were
mapped using the software Lasergene version 6.00 (DNASTAR,
Inc. USA) to determine the extent of overlapping sequences.
Sequencing multiple clones of three DEN-4 fragments
Three DNA fragments were synthesized from DEN-4 RNA by
RT-PCR using PlatinumH Pfx DNA polymerase with their
respective forward and reverse primer sets: (i) WE1/W02R, (ii)
W28/W29R, and (iii) W21/W23R (see Table S1 for sequences
and their genomic locations). Each of these DNA fragments was
inserted into pGEM T-easy cloning vector to obtain 10 or more
independent clones for sequence analysis. The sequences were
aligned in the WE1/W02R region (1,653-bp), the W28/W29R
region (1,260-bp), and the W21/W23R region (1,278-bp) using
the program Lasergene version 6.00 to generate the consensus
sequence for each of the three fragemnts. The mean diversity of
amino acids was determined as the number of amino acid
substitutions divided by the total number amino acids sequenced
[32,34,35]. Pair wise comparisons of amino acid sequences
between clones were performed to determine the mean and range
of pair wise distance matrix (p-distance) using the program MEGA
version 3.1 (Molecular Evolutionary Genetics Analysis, Pennsyl-
vania State University, PA). The p-distance is the proportion of
Dengue Virus Genetic Stability
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are different.
Supporting Information
Table S1 Primers used in the genomic sequencing of cloned
DNA-derived DEN-4 viruses in cell cultures.
Found at: doi:10.1371/journal.pone.0001810.s001 (0.18 MB
DOC)
Figure S1 Production of DEN-1 virus (HAWAII strain) from
Vero and MRC-5 cells grown on 2g/l Cytodex 1 microcarriers:
(A) Vero cell growth curves; (B) MRC-5 cell growth curves; (C)
virus replication curves in Vero cells; (D) virus replication curves
produced in MRC-5 cells.
Found at: doi:10.1371/journal.pone.0001810.s002 (0.06 MB TIF)
Figure S2 Production of DEN-2 virus (NGC strain) from Vero
and MRC-5 cells grown on 2g/l Cytodex 1 microcarriers.
Symbols are the same as Fig.S1.
Found at: doi:10.1371/journal.pone.0001810.s003 (0.06 MB TIF)
Figure S3 Production of DEN-3 virus (H-87 strain) from Vero
and MRC-5 cells grown on 2g/l Cytodex 1 microcarriers.
Symbols are the same as Fig. S1.
Found at: doi:10.1371/journal.pone.0001810.s004 (0.06 MB
TIF)
Figure S4 Production of DEN-4 virus (H-241 strain) from Vero
and MRC-5 cells grown on 2g/l Cytodex 1 microcarriers.
Symbols are the same as Fig. S1.
Found at: doi:10.1371/journal.pone.0001810.s005 (0.06 MB TIF)
Figure S5 Production of cloned DNA-derived DEN4 from Vero
and MRC-5 cells grown on 2g/l Cytodex 1 microcarriers.
Symbols are the same as Fig. S1.
Found at: doi:10.1371/journal.pone.0001810.s006 (0.06 MB TIF)
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